Fatima Sfifou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fatima Sfifou has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Abderrahmane Al Bouzidi
Research's Pedagogic Unit of Pathological Anatomy, Laboratory of Pathological Anatomy, Research Team in Tumour Pathology, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
2 shared publicationsAbdessamad El Ouahabi
Neurosurgery Department, Hospital of Specialities in Rabat, Morocco
2 shared publicationsEl Mehdi Hakkou
Neurosurgery Department, Hospital of Specialities in Rabat, Morocco
2 shared publicationsHassan Errihani
National Oncology Centre Sidi Mohamed Ben Abdallah in Rabat, Morocco
2 shared publicationsNadia Cherradi
Research's Pedagogic Unit of Pathological Anatomy, Laboratory of Pathological Anatomy, Research Team in Tumour Pathology, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco; Pathological Anatomy Department, Hospital of Specialities in Rabat, Morocco
2 shared publicationsRedouane Abouqal
Laboratory of Biostatistics, Clinical Research and Epidemiology, Rabat Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
2 shared publications
Latest Publications
- 1 January 2022
- Published by Elsevier in Journal of Chemical Neuroanatomy
- Vol. 119, 102056
Immunohistochemical expression of HIF-1α, IDH1 and TP53: Prognostic profile of Moroccan patients with diffuse glioma
- 1 January 2022
- Published by Elsevier in Journal of Chemical Neuroanatomy
- Vol. 119, 102056
Immunohistochemical expression of HIF-1α, IDH1 and TP53: Prognostic profile of Moroccan patients with diffuse glioma
- Open Access
- 17 August 2021
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 69, 102731
Correlation of immunohistochemical expression of HIF-1alpha and IDH1 with clinicopathological and therapeutic data of moroccan glioblastoma and survival analysis
Introduction: Glioblastomas are aggressive primary intracranial tumours of the central nervous system causing significant mortality and morbidity worldwide. Objective: This study aims to evaluate the prognostic value of tissue expression by immunostaining of hypoxiainducible factor (HIF-1 alpha), isocitrate dehydrogenase 1 (IDH1), and tumour protein p53 in glioblastoma in Moroccan patients. The association of HIF-1 alpha, IDH1, and p53 expression with the clinicopathological data and overall patient survival (OS) was also evaluated. Materials and methods: Confirmed glioblastomas were included in this study. Twenty-two tissue samples were obtained by neurosurgical intervention resulting from total resection, and subtotal resection or biopsy. Karnofsky index, histological type of tumour, and the status of IDH1, p53 protein, and HIF-1 alpha expression by immunostaining were reported. Results: The majority of the patients were males (64%) with a sex ratio of 1.75. The average age was 54 +/- 13. Median follow-up was 10.10 months and median overall survival was 10 months. The expression of HIF-1 alpha was high in 10 samples (45%) and low in 12 (55%). There was a statistically significant difference in OS of 85% at 12 months for the subgroup of patients "HIF-1 alpha negative IDH1 positive" p = 0.038, the unadjusted analysis showed that the group "HIF-1 alpha positive, IDH1 positive" was a poor prognostic factor, the HR was 0.08 (95% CI: 0.009-0.756, p = 0.027). Conclusion: Patients with negative HIF-1 alpha expression and positive IDH1 expression have a better prognosis, suggesting that these two biomarkers may be useful in the search for new approaches for targeted therapy in glioblastoma.
- 17 August 2021
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 69, 102731
Open AccessCorrelation of immunohistochemical expression of HIF-1alpha and IDH1 with clinicopathological and therapeutic data of moroccan glioblastoma and survival analysis
Introduction: Glioblastomas are aggressive primary intracranial tumours of the central nervous system causing significant mortality and morbidity worldwide. Objective: This study aims to evaluate the prognostic value of tissue expression by immunostaining of hypoxiainducible factor (HIF-1 alpha), isocitrate dehydrogenase 1 (IDH1), and tumour protein p53 in glioblastoma in Moroccan patients. The association of HIF-1 alpha, IDH1, and p53 expression with the clinicopathological data and overall patient survival (OS) was also evaluated. Materials and methods: Confirmed glioblastomas were included in this study. Twenty-two tissue samples were obtained by neurosurgical intervention resulting from total resection, and subtotal resection or biopsy. Karnofsky index, histological type of tumour, and the status of IDH1, p53 protein, and HIF-1 alpha expression by immunostaining were reported. Results: The majority of the patients were males (64%) with a sex ratio of 1.75. The average age was 54 +/- 13. Median follow-up was 10.10 months and median overall survival was 10 months. The expression of HIF-1 alpha was high in 10 samples (45%) and low in 12 (55%). There was a statistically significant difference in OS of 85% at 12 months for the subgroup of patients "HIF-1 alpha negative IDH1 positive" p = 0.038, the unadjusted analysis showed that the group "HIF-1 alpha positive, IDH1 positive" was a poor prognostic factor, the HR was 0.08 (95% CI: 0.009-0.756, p = 0.027). Conclusion: Patients with negative HIF-1 alpha expression and positive IDH1 expression have a better prognosis, suggesting that these two biomarkers may be useful in the search for new approaches for targeted therapy in glioblastoma.